Myelomatosis after phenytoin therapy: a chance association?
The occurrence of a monoclonal gammopathy followed by IgG-lambda multiple myeloma is described in a patient receiving diphenylhydantoin therapy for 20 years for epilepsy. Despite the known association between the drug and the development of immunosuppression and lymphoma, we regard the association recorded in this case to be coincidence. It is suggested that periodic examination of the serum proteins in patients receiving the drug may be useful in detecting early aberrations of the immune system in these individuals.
D000361:Agammaglobulinemia / Q000139:chemically induced; D001859:Bone Neoplasms / Q000139:chemically induced*; D006801:Humans; D007074:Immunoglobulin G; D007146:Immunoglobulin lambda-Chains; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000139:chemically induced*; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use
D007074:Immunoglobulin G; D007146:Immunoglobulin lambda-Chains; D010672:Phenytoin